Silence Therapeutics’ siRNA asset showed hints of efficacy in cardiovascular disease patients enrolled in a Phase I trial amid recent readouts from pipeline rivals backed by Big Pharma companies.
The biotech’s drug, zerlasiran, is designed to lower the body’s production of lipoprotein(a), or Lp(a), which is considered a genetic risk factor for cardiovascular disease.
The Phase I APOLLO trial studied zerlasiran in 36 people with stable atherosclerotic cardiovascular disease (ASCVD) and baseline Lp(a) levels of at least 150 nmol/L. In the placebo-controlled portion, three different doses of zerlasiran were administered to patients twice at different intervals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.